Cat. No.: DPP-001182
Product Overview | |
---|---|
Species | Human |
Format | Liquid |
Purity | ≥ 90% by SDS-PAGE |
Nature | Synthetic |
Target Information | |
---|---|
Gene Name | LRP2 |
UniProt No. | P98164 |
Gene ID | 4036 |
Alternative Names | Calcium sensor protein; DBS; Glycoprotein 330; gp330; Heymann nephritis antigen homolog; Low-density lipoprotein receptor-related protein 2; LRP-2; Lrp2; LRP2_HUMAN; Megalin |
Function | Acts together with cubilin to mediate HDL endocytosis (By similarity). May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release. |
Involvement In Disease | Defects in LRP2 are the cause of Donnai-Barrow syndrome (DBS); also known as faciooculoacousticorenal syndrome (FOAR syndrome). DBS is a rare autosomal recessive disorder characterized by major malformations including agenesis of the corpus callosum, congenital diaphragmatic hernia, facial dysmorphology, ocular anomalies, sensorineural hearing loss and developmental delay. The FOAR syndrome was first described as comprising facial anomalies, ocular anomalies, sensorineural hearing loss, and proteinuria. DBS and FOAR were first described as distinct disorders but the classic distinguishing features between the 2 disorders were presence of proteinuria and absence of diaphragmatic hernia and corpus callosum anomalies in FOAR. Early reports noted that the 2 disorders shared many phenotypic features and may be identical. Although there is variability in the expression of some features (e.g. agenesis of the corpus callosum and proteinuria), DBS and FOAR are now considered to represent the same entity. |
Cellular Localization | Membrane. Membrane > coated pit. |
Protein Family/Domains | Belongs to the LDLR family. Contains 17 EGF-like domains. Contains 36 LDL-receptor class A domains. Contains 37 LDL-receptor class B repeats. |
Shipping & Storage | |
---|---|
Shipping | Shipped on dry ice. |
Storage | Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.